Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: One strategy, many outcomes

Future Medicinal Chemistry

Volumn 4, Issue 1, 2012, Pages 51-72

  Wesierska Gadek, Józefa ^a   Składanowski, Andrzej ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ACLARUBICIN; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CEP 9722; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); INIPARIB; INO 1001; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RAZOXANE; SOBUZOXANE; SURAMIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATALYSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL KILLING; CELL PROLIFERATION; CHROMATIN CONDENSATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA CLEAVAGE; DNA RECOMBINATION; DNA REPAIR; DNA REPLICATION; DNA SUPERCOILING; DNA SYNTHESIS; DNA TRANSCRIPTION; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; LYMPHOMA; MELANOMA; MITOSIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE STRANDED DNA BREAK; SOLID TUMOR;

ANIMALS; DNA REPAIR; GENES, BRCA1; GENES, BRCA2; GENOMIC INSTABILITY; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

EID: 83655183806     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.175     Document Type: Review

References (228)

1. Norbury C, Nurse P. Animal cell cycles and their control. Ann. Rev. Biochem. 61, 441-470 (1992).
2. Morgan DO. Cyclin-dependent kinases. engines, clocks and microprocessors. Ann. Rev. Cell Dev. Biol. 13, 261-291 (1997). (Pubitemid 28034527)
3. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13(12), 1501-1512 (1999). (Pubitemid 29297917)
4. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 14(2), 159-169 (2008). (Pubitemid 351189186)
5. Muraoka RS, Lenferink AE, Simpson J et al. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J. Cell Biol. 153(5), 917-932 (2001).
6. Caldon CE, Sutherland RL, Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 9(10), 1918-1928 (2010).
7. Forcales SV, Puri PL. Signaling to the chromatin during skeletal myogenesis: novel targets for pharmacological modulation of gene expression. Semin. Cell Dev. Biol. 16(4-5), 596-611 (2005).
8. Champoux JJ. DNA topoisomerases: structure, function and mechanism. Ann. Rev. Biochem. 70, 369-413(2001).
9. Wang JC. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 31(2), 107-144 (1998).
10. Sundin O, Varshavsky A. Arrest of segregation leads to accumulation of highly intertwined catenated dimers: dissection of the final stages of SV40 DNA replication. Cell 25(3), 659-669 (1981). (Pubitemid 11022967)
11. Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 41(1), 41-101 (2008).
12. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9(5), 338-350 (2009).
13. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259(14), 9182-9187 (1984).
14. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673), 466-468 (1984). (Pubitemid 14012819)
15. Kohn KW, Pommier Y, Kerrigan D, Markovits J, Covey JM. Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr. (4), 61-71 (1987). (Pubitemid 17138177)
16. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49(18), 5016-5022 (1989). (Pubitemid 19239335)
17. Sekiguchi J, Shuman S. Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I. Mol. Cell 1(1), 89-97 (1997). (Pubitemid 127376396)
18. Rossi F, Labourier E, Forne T et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381(6577), 80-82 (1996). (Pubitemid 26130007)
19. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 99(2), 167-181 (2003).
20. Sorensen BS, Jensen PB, Sehested M et al. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem. Pharmacol. 47(11), 2105-2110 (1994). (Pubitemid 24192067)
21. Bridewell DJ, Finlay GJ, Baguley BC. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol. Res. 9(10), 535-542 (1997). (Pubitemid 127761179)
22. Nitiss JL, Pourquier P, Pommier Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res. 57(20), 4564-4569 (1997). (Pubitemid 27441062)
23. Calvo E, Cortes J, Rodriguez J et al. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. Cancer 92(9), 2435-2443(2001). (Pubitemid 33029090)
24. Grossman SA, Phuphanich S, Lesser G et al. Toxicity, efficacy and pharmacology of suramin in adults with recurrent high-grade gliomas. J. Clin. Oncol. 19(13), 3260-3266 (2001). (Pubitemid 32591444)
25. Knox JJ, Moore MJ. Treatment of hormone refractory prostate cancer. Semin. Urol. Oncol. 19(3), 202-211 (2001). (Pubitemid 32816500)
26. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl Acad. Sci. USA 89(7), 3025-3029 (1992).
27. Larsen AK, Escargueil AE, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog. Cell Cycle Res. 5, 295-300 (2003).
28. Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 61(5), 739-749 (2008). (Pubitemid 351302029)
29. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5(1), 1-28 (1998). (Pubitemid 28083490)
30. Bojanowski K, Filhol O, Cochet C, Chambaz EM, Larsen AK. DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J. Biol. Chem. 268(30), 22920-22926 (1993). (Pubitemid 23318358)
31. Gobert C, Bracco L, Rossi F et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry 35(18), 5778-5786 (1996). (Pubitemid 26143674)
32. Yamane K, Kawabata M, Tsuruo T. A DNA-topoisomerase-II-binding protein with eight repeating regions similar to DNA-repair enzymes and to a cell-cycle regulator. Eur. J. Biochem. 250(3), 794-799 (1997). (Pubitemid 28022498)
33. Kurz EU, Leader KB, Kroll DJ, Clark M, Gieseler F. Modulation of human DNA topoisomerase II alpha function by interaction with 14-13-3epsilon. J. Biol. Chem. 275(18), 13948-13954 (2000). (Pubitemid 30257472)
34. Escargueil AE, Plisov SY, Skladanowski A et al. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J. 15(12), 2288-2290 (2001).
35. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277(2), 1599-1606 (2002). (Pubitemid 34968919)
36. Bigioni M, Zunino F, Tinelli S, Austin CA, Willmore E, Capranico G. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity. Biochemistry 35(1), 153-159 (1996). (Pubitemid 26036418)
37. Kingma PS, Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J. Biol. Chem. 272(11), 7488-7493(1997). (Pubitemid 27166462)
38. Kingma PS, Osheroff N. Apurinic sites are position-specific topoisomerase II poisons. J. Biol. Chem. 272(2), 1148-1155(1997). (Pubitemid 27034611)
39. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272(42), 26441-26447 (1997). (Pubitemid 27458862)
40. Pourquier P, Ueng LM, Kohlhagen G et al. Effects of uracil incorporation, DNA mismatches and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 272(12), 7792-7796 (1997). (Pubitemid 27137335)
41. Kovalsky OI, Grossman L, Ahn B. The topodynamics of incision of UV-irradiated covalently closed DNA by the Escherichia coli Uvr(A)BC endonuclease. J. Biol. Chem. 271(52), 33236-33241 (1996). (Pubitemid 27010131)
42. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y. Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int. J. Cancer 62(1), 70-75(1995).
43. Fukuda M, Nishio K, Kanzawa F et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 56(4), 789-793(1996).
44. Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl Cancer Inst. 88(11), 734-741 (1996). (Pubitemid 26195021)
45. Mo YY, Yu Y, Ee PL, Beck WT. Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res. 64(8), 2793-2798 (2004). (Pubitemid 38500617)
46. Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 62(13), 3716-3721 (2002).
47. Eder JP Jr, Chan VT, Ng SW et al. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res. 55(24), 6109-6116 (1995).
48. Tan KB, Mattern MR, Boyce RA, Hertzberg RP, Schein PS. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. NCI Monogr. (4), 95-98 (1987). (Pubitemid 17138182)
49. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomeraseI complexes. Science 286(5439), 552-555(1999).
50. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 461(7264), 674-678 (2009).
51. Zeng Z, Cortes-Ledesma F, El Khamisy SF, Caldecott KW. TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J. Biol. Chem. 286(1), 403-409 (2011).
52. Nitiss KC, Malik M, He X, White SW, Nitiss JL. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc. Natl Acad. Sci. USA 103(24), 8953-8958 (2006). (Pubitemid 43902515)
53. Perego P, Cossa G, Tinelli S et al. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem. Pharmacol. doi:10.1016/j. bcp.2011.09.021 (2011) (Epub ahead of print).
54. Huang SY, Pommier Y, Marchand C. Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther. Pat. 21(9), 1285-1292 (2011).
55. Toyoda Y, Yanagida M. Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance. Mol. Biol. Cell 17(5), 2287-2302 (2006). (Pubitemid 44011744)
56. Nasmyth K, Peters JM, Uhlmann F. Splitting the chromosome: cutting the ties that bind sister chromatids. Science 288(5470), 1379-1385(2000).
57. Koshland DE, Guacci V. Sister chromatid cohesion: the beginning of a long and beautiful relationship. Curr. Opin Cell Biol. 12(3), 297-301 (2000). (Pubitemid 30265058)
58. Hirano T. Chromosome cohesion, condensation, and separation. Ann. Rev. Biochem. 69, 115-144 (2000).
59. Xu H, Tomaszewski JM, Mckay MJ. Can corruption of chromosome cohesion create a conduit to cancer? Nat. Rev. Cancer 11(3), 199-210 (2011).
60. Strom L, Karlsson C, Lindroos HB et al. Postreplicative formation of cohesion is required for repair and induced by a single DNA break. Science 317(5835), 242-245(2007). (Pubitemid 47076199)
61. Losada A, Hirano T. Intermolecular DNA interactions stimulated by the cohesin complex in vitro: implications for sister chromatidcohesion. Curr. Biol. 11(4), 268-272 (2001). (Pubitemid 32185330)
62. Walowsky C, Fitzhugh DJ, Castano IB, Ju JY, Levin NA, Christman MF. The topoisomerase-related function gene TRF4 affects cellular sensitivity to the anti-tumor agent camptothecin. J. Biol. Chem. 274(11), 7302-7308 (1999).
63. Redon C, Pilch DR, Bonner WM. Genetic analysis of Saccharomyces cerevisiae H2A serine 129 mutant suggests a functional relationship between H2A and the sister-chromatid cohesion partners Csm3-Tof1 for the repair of topoisomerase I-induced DNA damage. Genetics 172(1), 67-76 (2006). (Pubitemid 43345473)
64. Strom L, Lindroos HB, Shirahige K, Sjogren C. Postreplicative recruitment of cohesin to double-strand breaks is required for DNA repair. Mol. Cell 16(6), 1003-1015(2004). (Pubitemid 40018409)
65. Unal E, Arbel-Eden A, Sattler U et al. DNA damage response pathway uses histone modification to assemble a double-strand break-specific cohesin domain. Mol. Cell 16(6), 991-1002 (2004). (Pubitemid 40018408)
66. Stephan AK, Kliszczak M, Dodson H, Cooley C, Morrison CG. Roles of vertebrate Smc5in sister chromatid cohesion and homologous recombinational repair. Mol. Cell. Biol. 31(7), 1369-1381 (2011).
67. Covo S, Westmoreland JW, Gordenin DA, Resnick MA. Cohesin is limiting for the suppression of DNA damage-induced recombination between homologous chromosomes. PLoS Genet. 6(7), e1001006 (2010).
68. Mankouri HW, Hickson ID. The RecQ helicase-topoisomerase III-Rmi1 complex: a DNA structure-specific 'dissolvasome'? Trends Biochem. Sci. 32(12), 538-546 (2007). (Pubitemid 350123052)
69. Laine JP, Opresko PL, Indig FE, Harrigan JA, Von Kobbe C, Bohr VA. Werner protein stimulates topoisomerase I DNA relaxation activity. Cancer Res. 63(21), 7136-7146 (2003). (Pubitemid 37413451)
70. Chakraverty RK, Kearsey JM, Oakley TJ et al. Topoisomerase III acts upstream of Rad53p in the S-phase DNA damage checkpoint. Mol. Cell Biol. 21(21), 7150-7162 (2001). (Pubitemid 32953469)
71. Agrelo R, Cheng WH, Setien F et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23), 8822-8827 (2006). (Pubitemid 43878103)
72. Otsuki M, Seki M, Kawabe Y et al. WRN counteracts the NHEJ pathway upon camptothecin exposure. Biochem. Biophys. Res. Commun. 355(2), 477-482 (2007). (Pubitemid 46282653)
73. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27(3), 247-254 (2001). (Pubitemid 32201842)
74. Heyer WD, Ehmsen KT, Liu J. Regulation of homologous recombination in eukaryotes. Ann. Rev. Genet. 44, 113-139 (2010).
75. Van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2(3), 196-206 (2001). (Pubitemid 33674018)
76. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Ann. Rev. Biochem. 79, 181-211 (2010).
77. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66-71 (1994). (Pubitemid 24345325)
78. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell 4(4), 511-518 (1999). (Pubitemid 29531131)
79. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res. 61(12), 4842-4850 (2001). (Pubitemid 32691900)
80. Snouwaert JN, Gowen LC, Latour AM et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of nonhomologous recombination that is corrected by expression of a brca1 transgene. Oncogene 18(55), 7900-7907 (1999). (Pubitemid 30066235)
81. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32(1), 180-184 (2002). (Pubitemid 34977215)
82. Bau DT, Mau YC, Shen CY. The role of BRCA1 in nonhomologous end-joining. Cancer Lett. 240(1), 1-8 (2006).
83. Zhong Q, Boyer TG, Chen PL, Lee WH. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res. 62(14), 3966-3970 (2002). (Pubitemid 34791061)
84. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restoRes. radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274(26), 18808-18812 (1999).
85. Meza JE, Brzovic PS, King MC, Klevit RE. Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. J. Biol. Chem. 274(9), 5659-5665(1999). (Pubitemid 29109218)
86. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273(10), 5858-5868 (1998). (Pubitemid 28124064)
87. Scully R, Chen J, Plug A et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88(2), 265-275(1997). (Pubitemid 28015875)
88. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 11(2), 138-148 (2010).
89. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003). (Pubitemid 36530000)
90. Shamoo Y. Structural insights into BRCA2 function. Curr. Opin Struct. Biol. 13(2), 206-211 (2003). (Pubitemid 36515149)
91. Pellegrini L, Venkitaraman A. Emerging functions of BRCA2 in DNA recombination. Trends Biochem. Sci. 29(6), 310-316 (2004). (Pubitemid 38968763)
92. Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene 26(56), 7720-7730 (2007). (Pubitemid 350242452)
93. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998). (Pubitemid 28164626)
94. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst. 96(22), 1659-1668 (2004). (Pubitemid 39585635)
95. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97(9), 2187-2195(2003). (Pubitemid 36444059)
96. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat 115(2), 359-363(2009).
97. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1-and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 67(15), 7078-7081 (2007). (Pubitemid 47206532)
98. Hyman DM, Zhou Q, Arnold AG et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol. 123(2), 196-199 (2011).
99. Miyoshi Y, Kurosumi M, Kurebayashi J et al. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 17(2), 103-109 (2010).
100. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 19(24), 2925-2940 (2005). (Pubitemid 41798109)
101. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell 123(7), 1191-1198 (2005). (Pubitemid 41821778)
102. Kachnic LA, Li L, Fournier L et al. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett. 305(1), 86-93(2011).
103. Scully R, Chen J, Ochs RL et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90(3), 425-435(1997). (Pubitemid 27347233)
104. Feng Z, Kachnic L, Zhang J, Powell SN, Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J. Biol. Chem. 279(27), 28574-28584 (2004). (Pubitemid 38900140)
105. Wang H, Yang ES, Jiang J, Nowsheen S, Xia F. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res. 70(15), 6258-6267 (2010).
106. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11, 39-43(1963).
107. Brightwell M, Shall S. Poly(adenosine diphosphate ribose) polymerase in Physarum polycephalum nuclei. Biochem. J. 125(3), 67 (1971).
108. Ame JC, Spenlehauer C, De Murcia G. The PARP superfamily. Bioessays 26(8), 882-893(2004). (Pubitemid 39128102)
109. De Murcia G, Menissier De Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 19(4), 172-176 (1994). (Pubitemid 24115433)
110. Chalmers AJ. Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. Clin. Oncol. 16(1), 29-39 (2004). (Pubitemid 38195867)
111. Schreiber V, Dantzer F, Ame JC, De Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7(7), 517-528 (2006). (Pubitemid 44036457)
112. Ji Y, Tulin AV. The roles of PARP1 in gene control and cell differentiation. Curr. Opin Genet. Dev. 20(5), 512-518 (2010).
113. Lepiniec L, Babiychuk E, Kushnir S, Van Montagu M, Inze D. Characterization of an Arabidopsis thaliana cDNA homologue to animal poly(ADP-ribose) polymerase. FEBS Lett. 364(2), 103-108 (1995).
114. Shieh WM, Ame JC, Wilson MV et al. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. 273(46), 30069-30072 (1998). (Pubitemid 28545464)
115. Ame JC, Rolli V, Schreiber V et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. 274(25), 17860-17868 (1999).
116. Huppi K, Bhatia K, Siwarski D, Klinman D, Cherney B, Smulson M. Sequence and organization of the mouse poly(ADP-ribose) polymerase gene. Nucleic Acids Res. 17(9), 3387-3401 (1989). (Pubitemid 19120440)
117. Kawaichi M, Ueda K, Hayaishi O. Initiation of poly(ADP-ribosyl) histone synthesis by poly(ADP-ribose) synthetase. J. Biol. Chem. 255(3), 816-819 (1980).
118. Naegeli H, Loetscher P, Althaus FR. Poly ADP-ribosylation of proteins. Processivity of a post-translational modification. J. Biol. Chem. 264(24), 14382-14385(1989). (Pubitemid 19214270)
119. Wesierska-Gadek J, Sauermann G. Modification of nuclear matrix proteins by ADP-ribosylation. Association of nuclear ADP-ribosyltransferase with the nuclear matrix. Eur. J. Biochem. 153(2), 421-428 (1985). (Pubitemid 16209845)
120. Leitinger N, Wesierska-Gadek J. ADP-ribosylation of nucleolar proteins in HeLa tumor cells. J. Cell Biochem. 52(2), 153-158 (1993). (Pubitemid 23179290)
121. Wesierska-Gadek J, Bugajska-Schretter A, Cerni C. ADP-ribosylation of p53tumor suppressor protein: mutant but not wild-type p53is modified. J. Cell Biochem. 62(1), 90-101 (1996). (Pubitemid 26286285)
122. Huletsky A, Niedergang C, Frechette A, Aubin R, Gaudreau A, Poirier GG. Sequential ADP-ribosylation pattern of nucleosomal histones. ADP-ribosylation of nucleosomal histones. Eur. J. Biochem. 146(2), 277-285(1985). (Pubitemid 15168855)
123. Boulikas T. At least 60 ADP-ribosylated variant histones are present in nuclei from dimethylsulfate-treated and untreated cells. EMBO J. 7(1), 57-67 (1988).
124. Lindner H, Wesierska-Gadek J, Helliger W, Puschendorf B, Sauermann G. Identification of ADP-ribosylated histones by the combined use of high-performance liquid chromatography and electrophoresis. J. Chromatogr. 472(1), 243-249 (1989). (Pubitemid 19148946)
125. Kawaichi M, Ueda K, Hayaishi O. Multiple autopoly(ADP-ribosyl)ation of rat liver poly(ADP-ribose) synthetase. Mode of modification and properties of automodified synthetase. J. Biol. Chem. 256(18), 9483-9489 (1981).
126. Adamietz P. Poly(ADP-ribose) synthase is the major endogenous nonhistone acceptor for poly(ADP-ribose) in alkylated rat hepatoma cells. Eur. J. Biochem. 169(2), 365-372 (1987).
127. Zahradka P, Ebisuzaki K. A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase. Eur. J. Biochem. 127(3), 579-585(1982).
128. Sauermann G, Wesierska-Gadek J. Poly(ADP-ribose) effectively competes with DNA for histone H4 binding. Biochem. Biophys. Res. Commun. 139(2), 523-529 (1986). (Pubitemid 16002460)
129. Wesierska-Gadek J, Sauermann G. The effect of poly(ADP-ribose) on interactions of DNA with histones H1, H3and H4. Eur. J. Biochem. 173(3), 675-679 (1988).
130. Dantzer F, Ame JC, Schreiber V, Nakamura J, Menissier-De Murcia J, De Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol. 409, 493-510 (2006).
131. Okano S, Lan L, Caldecott KW, Mori T, Yasui A. Spatial and temporal cellular responses to single-strand breaks in human cells. Mol. Cell. Biol. 23(11), 3974-3981 (2003). (Pubitemid 36597475)
132. Wilson SH, Beard WA, Shock DD et al. Base excision repair and design of small molecule inhibitors of human DNA polymerase beta. Cell. Mol. Life Sci. 67(21), 3633-3647 (2010).
133. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J. 15(23), 6662-6670 (1996). (Pubitemid 26413798)
134. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31(17), 4959-4964 (2003). (Pubitemid 37441861)
135. Baumann C, Boehden GS, Burkle A, Wiesmuller L. Poly(ADP-ribose) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53. Nucleic Acids Res. 34(3), 1036-1049 (2006). (Pubitemid 43380686)
136. Wesierska-Gadek J, Wojciechowski J, Schmid G. Central and carboxy-terminal regions of human p53protein are essential for interaction and complex formation with PARP-1. J. Cell Biochem. 89(2), 220-232 (2003). (Pubitemid 36547256)
137. Wesierska-Gadek J, Wojciechowski J, Schmid G. Phosphorylation regulates the interactionand complex formation between wt p53protein and PARP-1. J. Cell Biochem. 89(6), 1260-1284 (2003). (Pubitemid 36969787)
138. Ahel I, Ahel D, Matsusaka T et al. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451(7174), 81-85(2008).
139. Gottschalk AJ, Timinszky G, Kong SE et al. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl Acad. Sci. USA 106(33), 13770-13774 (2009).
140. Ahel D, Horejsi Z, Wiechens N et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325(5945), 1240-1243(2009).
141. Rulten SL, Cortes-Ledesma F, Guo L, Iles NJ, Caldecott KW. APLF (C2orf13) is a novel component of poly(ADP-ribose) signaling in mammalian cells. Mol. Cell. Biol. 28(14), 4620-4628 (2008). (Pubitemid 351977759)
142. Malanga M, Czubaty A, Girstun A, Staron K, Althaus FR. Poly(ADP-ribose) binds to the splicing factor ASF/SF2 and regulates its phosphorylation by DNA topoisomerase I. J. Biol. Chem. 283(29), 19991-19998 (2008).
143. Chatterjee S, Hirschler NV, Petzold SJ, Berger SJ, Berger NA. Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability. Exp. Cell Res. 184(1), 1-15(1989). (Pubitemid 19233381)
144. Maclaren RA, Witmer MV, Richardson E, Stamato TD. Isolation of Chinese hamster ovary cells with reduced poly(ADP-ribose) polymerase activity. Mutat. Res. 231(2), 265-274 (1990). (Pubitemid 20252558)
145. Chatterjee S, Trivedi D, Petzold SJ, Berger NA. Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Cancer Res. 50(9), 2713-2718 (1990). (Pubitemid 20150210)
146. Chatterjee S, Cheng MF, Berger RB, Berger SJ, Berger NA. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res. 55(4), 868-873(1995).
147. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, Berger NA. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1(6), 389-394 (1989).
148. Chatterjee S, Cheng MF, Berger NA. Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2(12), 401-407 (1990).
149. Chatterjee S, Hirota H, Belfi CA, Berger SJ, Berger NA. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res. 57(22), 5112-5116 (1997). (Pubitemid 27498128)
150. Park SY, Cheng YC. Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin. Cancer Res. 65(9), 3894-3902 (2005).
151. Park SY, Leung CH, Cheng YC. ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin. Mol. Pharmacol. 73(6), 1829-1837 (2008).
152. Meyer-Ficca ML, Lonchar JD, Ihara M, Meistrich ML, Austin CA, Meyer RG. Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis. Biol. Reprod. 84(5), 900-909 (2011).
153. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 39(9), 3607-3620 (2011).
154. Wang ZQ, Auer B, Stingl L et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 9(5), 509-520 (1995).
155. De Murcia JM, Niedergang C, Trucco C et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA 94(14), 7303-7307 (1997). (Pubitemid 27345310)
156. Masutani M, Suzuki H, Kamada N et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 96(5), 2301-2304 (1999). (Pubitemid 29117909)
157. Shall S, De Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460(1), 1-15(2000). (Pubitemid 30365046)
158. Wang ZQ, Stingl L, Morrison C et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 11(18), 2347-2358 (1997). (Pubitemid 27408532)
159. Trucco C, Oliver FJ, De Murcia G, Menissier-De Murcia J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res. 26(11), 2644-2649 (1998). (Pubitemid 28297377)
160. Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to anti-tumor triazoloacridone C-1305is associated with permanent G2 cell cycle arrest. Cancer Res. 64(13), 4487-4497 (2004). (Pubitemid 38856920)
161. Wesierska-Gadek J, Wang ZQ, Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53protein in PARP-deficient mouse
162. Bürkle A, Schreiber V, Dantzer F et al. Biological significance of poly(ADP-ribosyl) ation reactions: molecular and genetic approaches. In: From DNA Damage and Stress Signaling to Cell Death. PolyADP-ribosylation Reactions., De Murcia G, Shall S (Eds). Oxford University Press, Oxford, UK 80-124 (2000).
163. Daniel RA, Rozanska AL, Thomas HD et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res. 15(4), 1241-1249 (2009).
164. Daniel RA, Rozanska AL, Mulligan EA et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br. J. Cancer 103(10), 1588-1596 (2010).
165. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 11(23), 8449-8457 (2005). (Pubitemid 41746960)
166. Delaney CA, Wang LZ, Kyle S et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6(7), 2860-2867 (2000). (Pubitemid 30482128)
167. Dobzhansky T. Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31(3), 269-290 (1946).
168. Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics 59(1), 37-44 (1968).
169. Hartman JLT, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science 291(5506), 1001-1004 (2001).
170. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5(9), 689-698 (2005). (Pubitemid 41486362)
171. Yap TA, Sandhu SK, Carden CP, De Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 61(1), 31-49 (2011).
172. Johnson N, Li YC, Walton ZE et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat. Med. 17(7), 875-882 (2011).
173. Bindra RS, Schaffer PJ, Meng A et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 24(19), 8504-8518 (2004). (Pubitemid 39245072)
174. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother. Oncol. 88(2), 258-268 (2008).
175. Albert JM, Cao C, Kim KW et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13(10), 3033-3042 (2007). (Pubitemid 46849580)
176. Barreto-Andrade JC, Efimova EV, Mauceri HJ et al. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol. Cancer Ther. 10(7), 1185-1193(2011).
177. Iliakis G, Wu W, Wang M. DNA double strand break repair inhibition as a cause of heat radiosensitization: re-evaluation considering backup pathways of NHEJ. Int. J. Hyperthermia 24(1), 17-29 (2008). (Pubitemid 351167616)
178. Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3multicentre study. Lancet Oncol. 11(6), 561-570 (2010).
179. Krawczyk PM, Eppink B, Essers J et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc. Natl Acad. Sci. USA 108(24), 9851-9856 (2011).
180. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5(4), 387-393(2011).
181. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin Pharmacol. 6(4), 364-368 (2006). (Pubitemid 44040837)
182. Plummer R, Jones C, Middleton M et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14(23), 7917-7923(2008).
183. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005). (Pubitemid 40559006)
184. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913-917 (2005). (Pubitemid 40559005)
185. Sandhu SK, Yap TA, De Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer 46(1), 9-20 (2010).
186. Chalmers AJ. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med. Chem. 10(7), 520-533(2010).
187. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 10(8), 1192-1199 (2011).
188. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
189. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235-244 (2010).
190. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737), 245-251 (2010).
191. Kummar S, Chen A, Ji J et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626 (2011).
192. Sasine JP, Savaraj N, Feun LG. Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends. Anticancer Agents Med. Chem. 10(9), 683-696 (2010).
193. Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol. Med. 17(7-8), 854-862 (2011).
194. Irshad S, Ashworth A, Tutt A. Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev. Anticancer Ther. 11(8), 1243-1251 (2011).
195. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105(8), 1114-1122 (2011).
196. Balmaña J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 1(1), 29-34 (2011).
197. Boulton S, Pemberton LC, Porteous JK et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer 72(4), 849-856 (1995).
198. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 77(6), 408-422 (1995).
199. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer 84(1), 106-112 (2001). (Pubitemid 32102513)
200. Tentori L, Leonetti C, Scarsella M et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99(6), 2241-2244 (2002). (Pubitemid 34525513)
201. Cimmino G, Pepe S, Laus G et al. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Pharmacol. Res. 55(1), 49-56 (2007). (Pubitemid 46108587)
202. D'Onofrio G, Tramontano F, Dorio AS et al. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. Biochem. Pharmacol. 81(2), 194-202 (2011).
203. Miknyoczki SJ, Jones-Bolin S, Pritchard S et al. Chemopotentiation of temozolomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2(4), 371-382 (2003).
204. Calabrese CR, Batey MA, Thomas HD et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 9(7), 2711-2718 (2003). (Pubitemid 36842117)
205. Tentori L, Leonetti C, Scarsella M et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/ temozolomide efficacy against colon carcinoma. FASEB J. 20(10), 1709-1711 (2006).
206. Miknyoczki S, Chang H, Grobelny J et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 6(8), 2290-2302 (2007). (Pubitemid 47294757)
207. Wurzer G, Herceg Z, Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res. 60(15), 4238-4244 (2000). (Pubitemid 30636611)
208. Saxena A, Saffery R, Wong LH, Kalitsis P, Choo KH. Centromere proteins Cenpa, Cenpb and Bub3interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated. J. Biol. Chem. 277(30), 26921-26926 (2002). (Pubitemid 34951701)
209. Monaco L, Kolthur-Seetharam U, Loury R, Murcia JM, De Murcia G, Sassone-Corsi P. Inhibition of aurora-B kinase activity by poly(ADP-ribosyl) ation in response to DNA damage. Proc. Natl Acad. Sci. USA 102(40), 14244-14248 (2005). (Pubitemid 41429683)
210. Haince JF, Kozlov S, Dawson VL et al. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J. Biol. Chem. 282(22), 16441-16453(2007). (Pubitemid 47100334)
211. Ullrich O, Reinheckel T, Sitte N, Hass R, Grune T, Davies KJ. Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. Proc. Natl Acad. Sci. USA 96(11), 6223-6228 (1999). (Pubitemid 29256647)
212. Zhang A, Lyu YL, Lin CP et al. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J. Biol. Chem. 281(47), 35997-36003(2006). (Pubitemid 46041332)
213. Von Metzler I, Heider U, Mieth M et al. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp. Cell Res. 315(14), 2471-2478 (2009).
214. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J. Experimental anti-tumor activity and toxicity of the selected triazolo-and imidazoacridinones. Arch. Immunol. Ther. Exp. 42(5-6), 415-423(1994).
215. Lemke K, Poindessous V, Skladanowski A, Larsen AK. The anti-tumor triazoloacridone C-1305is a topoisomerase II poison with unusual properties. Mol. Pharmacol. 66(4), 1035-1042 (2004). (Pubitemid 39319476)
216. Maurer M, Komina O, Skladanowski A, Wesierska-Gadek J. Triazoloacridone C-1305abrogates the restriction checkpoint in cells lacking functional p53and promotes their accumulation in the G2/M phase of the cell cycle. J. Exp. Ther. Oncol. 9(1), 5-15(2011).
217. Sabisz M, Wesierska-Gadek J, Skladanowski A. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53pathway and modulation of mitotic checkpoints. Biochem. Pharmacol. 79(10), 1387-1397 (2010).
218. Bryant HE, Petermann E, Schultz N et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28(17), 2601-2615(2009).
219. Schreiber V, Ame JC, Dolle P et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277(25), 23028-23036 (2002). (Pubitemid 34967289)
220. Rouleau M, Mcdonald D, Gagne P et al. PARP-3associates with polycomb group bodies and with components of the DNA damage repair machinery. J. Cell. Biochem. 100(2), 385-401 (2007). (Pubitemid 46146088)
221. Loseva O, Jemth AS, Bryant HE et al. PARP-3is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA. J. Biol. Chem. 285(11), 8054-8060 (2010).
222. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res. 50(1), 38-43(1990). (Pubitemid 20029990)
223. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am. J. Hematol 37(4), 223-227 (1991).
224. Shiobara M, Miyazaki M, Ito H et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 16(3), 338-344 (2001). (Pubitemid 32374852)
225. Mcellin B, Camacho CV, Mukherjee B et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70(13), 5457-5464 (2010).
226. Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1(6-7), 315-322 (2009).
227. Williamson CT, Muzik H, Turhan AG et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 9(2), 347-357 (2010).
228. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075(2008).